Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related 		KEGG GENES KEGG DRUG DrugBank 指定難病告示番号
1 Adipocytokine signaling pathway 💬
 1件: JAK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
2 Adipocytokine signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
3 Adipocytokine signaling pathway 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
4 African trypanosomiasis 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
5 African trypanosomiasis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
6 African trypanosomiasis 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
7 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: JAK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
8 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
9 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
10 Alcoholic liver disease 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
11 Alcoholic liver disease 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
12 Alcoholic liver disease 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
13 Allograft rejection 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
14 Allograft rejection 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
15 Allograft rejection 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
16 Alzheimer disease 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
17 Alzheimer disease 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
18 Alzheimer disease 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
19 Amoebiasis 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
20 Amoebiasis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
21 Amoebiasis 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
22 Amphetamine addiction 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
23 Amyotrophic lateral sclerosis 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
24 Amyotrophic lateral sclerosis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
25 Amyotrophic lateral sclerosis 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
26 Antifolate resistance 💬
 2件: DHFR, DHFR2 💬 D00142 💬 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬
27 Antifolate resistance 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
28 Antifolate resistance 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
29 Antigen processing and presentation 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
30 Antigen processing and presentation 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
31 Apoptosis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
32 Apoptosis 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
33 Asthma 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
34 Asthma 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
35 Axon guidance 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
36 B cell receptor signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
37 Biosynthesis of cofactors 💬
 2件: DHFR, DHFR2 💬 D00142 💬 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬
38 Biosynthesis of cofactors 💬
 1件: DHODH 💬 D00749 💬 Leflunomide 12件: 11, 40, 46, 49, 53, 66, 107, 162, 224, 270, 271, 300 💬
39 C-type lectin receptor signaling pathway 💬
 3件: IL12A, IL12B, IL23A 💬 D09214 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
40 C-type lectin receptor signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
41 C-type lectin receptor signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
42 C-type lectin receptor signaling pathway 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
43 Calcium signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
44 Cellular senescence 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
45 cGMP-PKG signaling pathway 💬
 1件: OPRD1 💬 D05113 💬 Naltrexone 13件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 💬
46 cGMP-PKG signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
47 Chagas disease 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
48 Chagas disease 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
49 Chagas disease 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
50 Chemical carcinogenesis - receptor activation 💬
 1件: JAK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
51 Chemokine signaling pathway 💬
 2件: JAK2, JAK3 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
52 Cholinergic synapse 💬
 1件: JAK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
53 Coronavirus disease - COVID-19 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
54 Coronavirus disease - COVID-19 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
55 Coronavirus disease - COVID-19 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
56 Coronavirus disease - COVID-19 💬
 2件: JAK1, TYK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
57 Coronavirus disease - COVID-19 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
58 Coronavirus disease - COVID-19 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
59 Cytokine-cytokine receptor interaction 💬
 1件: CSF3R 💬 D03235 💬 Filgrastim 35件:  2 ,  6 , 11, 13, 16, 22, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬
60 Cytokine-cytokine receptor interaction 💬
 3件: IL12A, IL12B, IL23A 💬 D09214 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
61 Cytokine-cytokine receptor interaction 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
62 Cytokine-cytokine receptor interaction 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
63 Cytokine-cytokine receptor interaction 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
64 Dilated cardiomyopathy 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
65 Dilated cardiomyopathy 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
66 Dopaminergic synapse 💬
 3件: PPP3CA, PPP3CB, PPP3CC 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
67 EGFR tyrosine kinase inhibitor resistance 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
68 EGFR tyrosine kinase inhibitor resistance 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
69 EGFR tyrosine kinase inhibitor resistance 💬
 2件: JAK1, JAK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
70 Epstein-Barr virus infection 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
71 Epstein-Barr virus infection 💬
 3件: JAK1, JAK3, TYK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
72 Epstein-Barr virus infection 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
73 Epstein-Barr virus infection 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
74 Estrogen signaling pathway 💬
 1件: OPRM1 💬 D05113 💬 Naltrexone 13件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 💬
75 Fc epsilon RI signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
76 Fc epsilon RI signaling pathway 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
77 Fluid shear stress and atherosclerosis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
78 Fluid shear stress and atherosclerosis 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
79 Folate biosynthesis 💬
 2件: DHFR, DHFR2 💬 D00142 💬 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬
80 Glucagon signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
81 Glutamatergic synapse 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
82 Graft-versus-host disease 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
83 Graft-versus-host disease 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
84 Growth hormone synthesis, secretion and action 💬
 1件: JAK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
85 Hematopoietic cell lineage 💬
 1件: CSF3R 💬 D03235 💬 Filgrastim 35件:  2 ,  6 , 11, 13, 16, 22, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬
86 Hematopoietic cell lineage 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
87 Hematopoietic cell lineage 💬
 1件: MS4A1 💬 D02994 💬 Rituximab 48件: 11, 13, 14, 19, 26, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331 💬
88 Hematopoietic cell lineage 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
89 Hematopoietic cell lineage 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
90 Hepatitis B 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
91 Hepatitis B 💬
 4件: JAK1, JAK2, JAK3, TYK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
92 Hepatitis B 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
93 Hepatitis B 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
94 Hepatitis C 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
95 Hepatitis C 💬
 2件: JAK1, TYK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
96 Hepatitis C 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
97 Hepatitis C 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
98 Herpes simplex virus 1 infection 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
99 Herpes simplex virus 1 infection 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
100 Herpes simplex virus 1 infection 💬
 3件: JAK1, JAK2, TYK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
101 Herpes simplex virus 1 infection 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
102 Herpes simplex virus 1 infection 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
103 HIF-1 signaling pathway 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
104 Human cytomegalovirus infection 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
105 Human cytomegalovirus infection 💬
 1件: JAK1 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
106 Human cytomegalovirus infection 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
107 Human cytomegalovirus infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
108 Human cytomegalovirus infection 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
109 Human cytomegalovirus infection 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
110 Human immunodeficiency virus 1 infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
111 Human immunodeficiency virus 1 infection 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
112 Human immunodeficiency virus 1 infection 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
113 Human papillomavirus infection 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
114 Human papillomavirus infection 💬
 2件: JAK1, TYK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
115 Human papillomavirus infection 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
116 Human papillomavirus infection 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
117 Human T-cell leukemia virus 1 infection 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
118 Human T-cell leukemia virus 1 infection 💬
 2件: JAK1, JAK3 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
119 Human T-cell leukemia virus 1 infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
120 Human T-cell leukemia virus 1 infection 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
121 Human T-cell leukemia virus 1 infection 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
122 Hypertrophic cardiomyopathy 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
123 Hypertrophic cardiomyopathy 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
124 IL-17 signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
125 IL-17 signaling pathway 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
126 Inflammatory bowel disease 💬
 3件: IL12A, IL12B, IL23A 💬 D09214 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
127 Inflammatory bowel disease 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
128 Inflammatory bowel disease 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
129 Influenza A 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
130 Influenza A 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
131 Influenza A 💬
 3件: JAK1, JAK2, TYK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
132 Influenza A 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
133 Influenza A 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
134 Insulin resistance 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
135 Insulin resistance 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
136 JAK-STAT signaling pathway 💬
 1件: CSF3R 💬 D03235 💬 Filgrastim 35件:  2 ,  6 , 11, 13, 16, 22, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬
137 JAK-STAT signaling pathway 💬
 3件: IL12A, IL12B, IL23A 💬 D09214 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
138 JAK-STAT signaling pathway 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
139 JAK-STAT signaling pathway 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
140 JAK-STAT signaling pathway 💬
 4件: JAK1, JAK2, JAK3, TYK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
141 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
142 Kaposi sarcoma-associated herpesvirus infection 💬
 3件: JAK1, JAK2, TYK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
143 Kaposi sarcoma-associated herpesvirus infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
144 Legionellosis 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
145 Legionellosis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
146 Legionellosis 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
147 Leishmaniasis 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
148 Leishmaniasis 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
149 Leishmaniasis 💬
 2件: JAK1, JAK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
150 Leishmaniasis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
151 Leishmaniasis 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
152 Lipid and atherosclerosis 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
153 Lipid and atherosclerosis 💬
 1件: JAK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
154 Lipid and atherosclerosis 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
155 Lipid and atherosclerosis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
156 Lipid and atherosclerosis 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
157 Long-term potentiation 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
158 Malaria 💬
 1件: IL12A 💬 D09214 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
159 Malaria 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
160 Malaria 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
161 MAPK signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
162 MAPK signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
163 MAPK signaling pathway 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
164 Measles 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
165 Measles 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
166 Measles 💬
 3件: JAK1, JAK3, TYK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
167 Metabolic pathways 💬
 2件: DHFR, DHFR2 💬 D00142 💬 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬
168 Metabolic pathways 💬
 1件: DHODH 💬 D00749 💬 Leflunomide 12件: 11, 40, 46, 49, 53, 66, 107, 162, 224, 270, 271, 300 💬
169 Morphine addiction 💬
 1件: OPRM1 💬 D05113 💬 Naltrexone 13件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 💬
170 mTOR signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
171 mTOR signaling pathway 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
172 Natural killer cell mediated cytotoxicity 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
173 Natural killer cell mediated cytotoxicity 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
174 Natural killer cell mediated cytotoxicity 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
175 Necroptosis 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
176 Necroptosis 💬
 4件: JAK1, JAK2, JAK3, TYK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
177 Necroptosis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
178 Necroptosis 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
179 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D00407 💬 Methylprednisolone 46件:  2 , 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 85, 86, 93, 95, 96, 97, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296 💬
180 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D00472 💬 Prednisolone 42件:  3 , 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300 💬
181 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D00473 💬 Prednisone 45件:  2 , 11, 13, 14, 19, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 79, 81, 84, 85, 86, 95, 96, 97, 113, 162, 164, 205, 222, 224, 228, 283, 284, 288, 299, 300, 307, 331 💬
182 Neuroactive ligand-receptor interaction 💬
 3件: OPRD1, OPRK1, OPRM1 💬 D05113 💬 Naltrexone 13件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 💬
183 NF-kappa B signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
184 NF-kappa B signaling pathway 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
185 NOD-like receptor signaling pathway 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
186 NOD-like receptor signaling pathway 💬
 2件: JAK1, TYK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
187 NOD-like receptor signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
188 NOD-like receptor signaling pathway 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
189 Non-alcoholic fatty liver disease 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
190 Non-alcoholic fatty liver disease 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
191 Non-alcoholic fatty liver disease 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
192 Non-small cell lung cancer 💬
 1件: JAK3 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
193 One carbon pool by folate 💬
 2件: DHFR, DHFR2 💬 D00142 💬 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬
194 Oocyte meiosis 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
195 Osteoclast differentiation 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
196 Osteoclast differentiation 💬
 2件: JAK1, TYK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
197 Osteoclast differentiation 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
198 Osteoclast differentiation 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
199 Osteoclast differentiation 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
200 Oxytocin signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
201 Pancreatic cancer 💬
 1件: JAK1 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
202 Pancreatic cancer 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
203 Pathogenic Escherichia coli infection 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
204 Pathogenic Escherichia coli infection 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
205 Pathways in cancer 💬
 1件: CSF3R 💬 D03235 💬 Filgrastim 35件:  2 ,  6 , 11, 13, 16, 22, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬
206 Pathways in cancer 💬
 3件: IL12A, IL12B, IL23A 💬 D09214 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
207 Pathways in cancer 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
208 Pathways in cancer 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
209 Pathways in cancer 💬
 3件: JAK1, JAK2, JAK3 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
210 Pathways of neurodegeneration - multiple diseases 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
211 Pathways of neurodegeneration - multiple diseases 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
212 Pathways of neurodegeneration - multiple diseases 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
213 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
214 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 2件: JAK1, JAK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
215 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
216 Pertussis 💬
 3件: IL12A, IL12B, IL23A 💬 D09214 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
217 Pertussis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
218 Pertussis 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
219 PI3K-Akt signaling pathway 💬
 1件: CSF3R 💬 D03235 💬 Filgrastim 35件:  2 ,  6 , 11, 13, 16, 22, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬
220 PI3K-Akt signaling pathway 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
221 PI3K-Akt signaling pathway 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
222 PI3K-Akt signaling pathway 💬
 3件: JAK1, JAK2, JAK3 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
223 Primary immunodeficiency 💬
 1件: JAK3 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
224 Prion disease 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
225 Prion disease 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
226 Prion disease 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
227 Prolactin signaling pathway 💬
 1件: JAK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
228 Proteoglycans in cancer 💬
 1件: IL12B 💬 D09214 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
229 Proteoglycans in cancer 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
230 Proteoglycans in cancer 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
231 Pyrimidine metabolism 💬
 1件: DHODH 💬 D00749 💬 Leflunomide 12件: 11, 40, 46, 49, 53, 66, 107, 162, 224, 270, 271, 300 💬
232 Renin secretion 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
233 Rheumatoid arthritis 💬
 1件: IL23A 💬 D09214 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
234 Rheumatoid arthritis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
235 Rheumatoid arthritis 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
236 RIG-I-like receptor signaling pathway 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
237 RIG-I-like receptor signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
238 RIG-I-like receptor signaling pathway 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
239 Salmonella infection 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
240 Salmonella infection 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
241 Shigellosis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
242 Shigellosis 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
243 Signaling pathways regulating pluripotency of stem cells 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
244 Signaling pathways regulating pluripotency of stem cells 💬
 3件: JAK1, JAK2, JAK3 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
245 Sphingolipid signaling pathway 💬
 1件: OPRD1 💬 D05113 💬 Naltrexone 13件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 💬
246 Sphingolipid signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
247 Sphingolipid signaling pathway 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
248 Systemic lupus erythematosus 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
249 Systemic lupus erythematosus 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
250 T cell receptor signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
251 T cell receptor signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
252 T cell receptor signaling pathway 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
253 TGF-beta signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
254 TGF-beta signaling pathway 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
255 Th1 and Th2 cell differentiation 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
256 Th1 and Th2 cell differentiation 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
257 Th1 and Th2 cell differentiation 💬
 4件: JAK1, JAK2, JAK3, TYK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
258 Th1 and Th2 cell differentiation 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
259 Th17 cell differentiation 💬
 1件: IL23A 💬 D09214 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
260 Th17 cell differentiation 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
261 Th17 cell differentiation 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
262 Th17 cell differentiation 💬
 4件: JAK1, JAK2, JAK3, TYK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
263 Th17 cell differentiation 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
264 TNF signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
265 TNF signaling pathway 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
266 Toll-like receptor signaling pathway 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
267 Toll-like receptor signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
268 Toll-like receptor signaling pathway 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
269 Toxoplasmosis 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
270 Toxoplasmosis 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
271 Toxoplasmosis 💬
 3件: JAK1, JAK2, TYK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
272 Toxoplasmosis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
273 Toxoplasmosis 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
274 Tuberculosis 💬
 3件: IL12A, IL12B, IL23A 💬 D09214 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
275 Tuberculosis 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
276 Tuberculosis 💬
 2件: JAK1, JAK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
277 Tuberculosis 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
278 Tuberculosis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
279 Tuberculosis 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
280 Type I diabetes mellitus 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
281 Type I diabetes mellitus 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
282 Type I diabetes mellitus 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
283 Type II diabetes mellitus 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
284 Type II diabetes mellitus 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
285 VEGF signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
286 Viral carcinogenesis 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271 💬
287 Viral carcinogenesis 💬
 2件: JAK1, JAK3 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
288 Viral protein interaction with cytokine and cytokine receptor 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
289 Viral protein interaction with cytokine and cytokine receptor 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
290 Viral protein interaction with cytokine and cytokine receptor 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
291 Wnt signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
292 Yersinia infection 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
293 Yersinia infection 💬
 1件: TNF 💬 D02598 💬 Infliximab 27件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬

先頭へ